-
Fosun Pharmaceutical’s PD-1 Inhibitor HanSiZhuang Recommended for Approval by EMA’s CHMP
•
Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196), a leading pharmaceutical company in China, has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), recommending the approval of its anti-programmed death-1 (PD-1) inhibitor, HanSiZhuang, in combination with carboplatin and…
-
Tencent’s We Doctor Partners with CHA on National Digital Health Platform and Academic Initiatives
•
We Doctor, a subsidiary of Chinese internet conglomerate Tencent Corporate Venture Capital (HKG: 0700) specializing in online medical services, has entered into a strategic partnership with the Chinese Health Association (CHA). The collaboration aims to explore innovative models focused on ‘common health’ and ‘universal health.’ As part of this initiative,…
-
Huadong Medicine Secures Exclusive Rights to Janagliflozin for Type 2 Diabetes Treatment in China
•
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has entered into a licensing agreement with fellow Chinese firm Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460), securing exclusive commercialization rights for Sihuan’s Category 1 drug, janagliflozin, in mainland China. Under the terms of the agreement, Huadong will handle the…
-
AstraZeneca’s HIMALAYA Trial Data Showcases Significant Survival Benefits for Liver Cancer Treatment at ESMO 2024
•
At the European Society for Medical Oncology (ESMO) 2024 conference, AstraZeneca (NASDAQ: AZN, LON: AZN) presented updated data from the HIMALAYA Phase III trial, demonstrating sustained and clinically meaningful overall survival (OS) benefits for patients with unresectable hepatocellular carcinoma (HCC) who had not previously received systemic therapy and for whom…
-
Aligos Therapeutics’ ALG-055009 Achieves Positive Topline Results in Phase 2a HERALD Study for MASH
•
Aligos Therapeutics, a clinical-stage biopharmaceutical company focused on liver and viral diseases, has announced positive topline results from its Phase 2a HERALD study for ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in patients with metabolic dysfunction-associated steatohepatitis (MASH). The study, which is the first to demonstrate the benefits of…
-
Roche’s Xofluza Receives FDA Approval for Reducing Influenza Transmission in Phase III Study
•
Roche (SWX: ROG; OTCMKTS: RHHBY) has announced that its antiviral drug Xofluza (baloxavir marboxil) has received approval from the US Food and Drug Administration (FDA) based on positive results from the Phase III CENTERSTONE study. The study demonstrated that a single dose of Xofluza significantly reduced the transmission of influenza…
-
J&J’s Rybrevant Secures FDA Approval for EGFR/c-MET Non-Small Cell Lung Cancer Treatment
•
Johnson & Johnson (J&J; NYSE: JNJ)has announced that the US Food and Drug Administration (FDA) has granted approval for its EGFR/c-MET bispecific antibody, Rybrevant (amivantamab-vmjw), in combination with standard chemotherapy, for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor…
-
Beijing’s Apollobio Receives NMPA Approval for HPV Therapeutic Vaccine VGX-3100
•
Beijing’s Apollobio, has announced that the National Medical Products Administration (NMPA) has granted market approval for its innovative therapeutic vaccine VGX-3100. This vaccine, which targets HPV-16/18 related anal precancerous lesions, is a significant advancement in the treatment landscape for conditions associated with Human Papillomavirus (HPV). The vaccine’s approval follows a…
-
Insilico Medicine’s AI-Generated Drug Candidate ISM001-055 Shows Positive Phase II Results in IPF Study
•
China-based artificial intelligence (AI) drug developer Insilico Medicine has reported initial positive data from its Phase IIa study for ISM001-055, an in-house generative AI-generated drug candidate for idiopathic pulmonary fibrosis (IPF). The molecule, which targets TNIK (Traf2- and NCK- interacting kinase), has shown a positive safety profile and dose-dependent lung…
-
Lee’s Pharmaceutical’s Zhaoke Ophthalmology Receives NMPA Approval for Generic Lumigan
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622), has announced that it has received market approval from China’s National Medical Products Administration (NMPA) for its generic version of Allergan’s (NYSE: AGN) Lumigan (bimatoprost), a treatment for glaucoma. The product, marketed under the Chinese trade…
-
Jiangsu Hengrui Pharmaceuticals’ SHR-1701 Combo Therapy for Gastric Cancer Accepted for Review by China’s NMPA
•
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that the National Medical Products Administration (NMPA) has accepted for review its market filing for SHR-1701 in combination with fluorouracil and platinum for the first-line treatment of locally advanced unresectable, recurrent, or metastatic adenocarcinoma of…
-
JiCui Cell Therapy Forms Partnership with Fosun Kite to Advance Bispecific CAR-T Cell Therapy Industrialization
•
JiCui Cell Therapy Drug Research Institute, also known as Jiangsu Jicui Juechuang Biotechnology Research Institute Co., Ltd, has entered into a strategic partnership with Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Gilead’s subsidiary Kite Pharma. The collaboration…
-
Apeloa Pharmaceutical Invests in Ji Xing Pharmaceuticals’ Series D Financing Round
•
China-based Apeloa Pharmaceutical Co., Ltd (SHE: 000739) has announced its participation in the Series D financing round of fellow Chinese firm Ji Xing Pharmaceuticals, contributing USD 2.75 million for a 0.58% stake in the Shanghai-based company. The investment round also saw contributions from Ji Xing’s founder, RTW Holding Limited, and…
-
CSPC Pharmaceutical Group Appoints Dr. Liu Yongjun as Group CEO and Global R&D President
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced the appointment of Dr. Liu Yongjun as its Group CEO and Global R&D President. Dr. Liu will be responsible for leading the company’s research and development, pipeline strategy, and global business development initiatives. Dr. Liu…
-
Sinopharm Holding Appoints New Chairman and President Following Leadership Changes
•
Sinopharm Holding (HKG: 1099) has announced significant changes in its leadership with the approval of its board of directors for the appointment of Zhao Bingxiang as the new chairman and Lian Wanyong as the president. This comes as former chairman Yu Qingming and president Liu Yong have stepped down from…
-
Sichuan Kelun-Biotech Reports 32.2% Revenue Growth in 2024 H1, Driven by MSD Partnership
•
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced its financial results for the first half of 2024, reporting a 32.2% year-on-year (YOY) increase in revenues to RMB 1.383 billion, which includes a USD 90 million cooperation payment from its U.S. partner Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK),.…
-
Ocumension Therapeutics’ Zerviate Receives Marketing Approval in China for Allergic Conjunctivitis Treatment
•
Ocumension Therapeutics (HKG: 1477), a leading ophthalmology specialist in China, has announced that its histamine H1 receptor-targeted drug Zerviate (OT-1001) has been granted marketing approval in China with priority review status. The drug is indicated for the treatment of itching symptoms associated with allergic conjunctivitis. Zerviate, originally developed by the…
-
Organon Inks Deal to Acquire Dermavant, Bolstering Dermatology Portfolio with Vtama Cream
•
US healthcare company Organon (NYSE: OGN) has announced a definitive agreement to acquire Dermavant, a Roivant (NASDAQ: ROIV) subsidiary focused on dermatological treatments. The acquisition is primarily driven by Dermavant’s Vtama (tapinarof) cream, a 1% topical formulation approved for plaque psoriasis and currently under regulatory review for atopic dermatitis (AD).…
-
MSD’s Keytruda Secures FDA Approval for First-Line Mesothelioma Treatment in Combination with Chemotherapy
•
Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced that the US Food and Drug Administration (FDA) has approved a new indication for its programmed death-1 (PD-1) inhibitor, Keytruda (pembrolizumab). The approval allows for the use of Keytruda in combination with pemetrexed and platinum chemotherapy as a first-line treatment…
-
AstraZeneca’s Fasenra Secures FDA Nod for EGPA Treatment, Strengthening Rare Disease Portfolio
•
UK pharmaceutical giant AstraZeneca (NASDAQ: AZN, LON: AZN) has announced that the US Food and Drug Administration (FDA) has approved a new indication for its interleukin-5 (IL-5)-targeted antibody, Fasenra (benralizumab), for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA), a rare and potentially fatal disease. The approval comes on the…
